Outcomes after sofosbuvir-containing regimens for hepatitis C virus in patients with decompensated cirrhosis: a real-world study
Abstract Background Direct-acting antivirals have been used for decompensated cirrhotic patients with hepatitis C virus (HCV) infection. However, the benefits in Chinese patients with decompensated cirrhosis are unclear. Methods Thirty patients with HCV infection and decompensated cirrhosis were adm...
Main Authors: | Fanpu Ji, Wenjun Wang, Shuangsuo Dang, Shengbang Wang, Burong Li, Dan Bai, Wenxue Zhao, Hong Deng, Changyin Tian, Zongfang Li |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-09-01
|
Series: | Infectious Agents and Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13027-017-0158-1 |
Similar Items
-
Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective, Multicenter Study
by: Masanori Atsukawa, et al.
Published: (2020-09-01) -
Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis
by: Steven Flamm, et al.
Published: (2023-09-01) -
Palmitoylcarnitine impairs immunity in decompensated cirrhosis
by: Ingrid Wei Zhang, et al.
Published: (2024-11-01) -
Risk factors and prognostic impact of new decompensated events in hospitalized patients with decompensated cirrhosis
by: Yan Lan, et al.
Published: (2024-11-01) -
Successful Treatment with Crushed Sofosbuvir/Velpatasvir of a Patient with Decompensated Cirrhosis C and Thrombocytopenia
by: Aiko Murayama, et al.
Published: (2021-08-01)